

Press release for immediate publishing, July 26, 2004

Monica Caneman new board member of Orexo AB

Orexo AB in Uppsala announces the election of Monica Caneman as new member of its Board of Directors. Monica Caneman previously worked for SEB, where she was employed for more than 20 years, the last four as Deputy CEO.

“Monica Caneman has her background at SEB (Skandinaviska Enskilda Banken), where she held several important and senior positions in finance and marketing. She holds a Board seat in a number of companies active in various businesses, which gives her a broad level of experience. This will be an important asset for a company like Orexo, which is in a fast expansion phase”, said Zsolt Lavotha, newly appointed CEO of Orexo AB.

Monica Caneman has an M.Sc from the Stockholm School of Economics and Business Administration. She is a member of several boards, i.e. Investment AB Öresund, SJ and Schibsted ASA.

Erik Helgstrand and Ülo Langel resigned from the Orexo Board.

Orexo is an Uppsala based pharmaceutical company, focused on drug delivery. Orexo specializes in different types of dry formulation based medicines, for oral administration. Its sublingual tablet, is today one of the company’s most important technological platforms.

For more information, please contact:

Zsolt Lavotha, President & CEO, Orexo AB
+46 (0)18 780 88 12, e-mail: zsolt.lavotha@orexo.se

Orexo AB (publ) is a Swedish pharmaceutical company established in 1995 based in Uppsala. Orexo develops, documents and registers patented pharmaceutical products based on innovative and proprietary drug formulations. This is carried out through in-house development, licensing or co-development with partners.

www.orexo.se